Anderson Rodrigues de Almeida
Overview
Explore the profile of Anderson Rodrigues de Almeida including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
de Oliveira Pedrosa Rolim M, de Almeida A, Pitta M, Barreto de Melo Rego M, Quintans-Junior L, Quintans J, et al.
Int Immunopharmacol
. 2019 Sep;
76:105856.
PMID: 31480005
The search for new drugs with anti-inflammatory properties remains a challenge for modern medicine. Among the various strategies for drug discovery, deriving new chemical entities from known bioactive natural and/or...
12.
Guimaraes Goncalves R, Pereira M, Dantas A, de Almeida A, Rego M, Lima E, et al.
Exp Dermatol
. 2019 Jun;
28(10):1172-1175.
PMID: 31162840
Although several cytokines and chemokines have been investigated as possible mediators of fibrosis in systemic sclerosis (SSc), specific correlation between cytokines and organ involvement have not been found yet, and...
13.
de Almeida A, Dantas A, Pereira M, Cordeiro M, Guimaraes Goncalves R, Barreto de Melo Rego M, et al.
Inflammopharmacology
. 2019 May;
27(4):723-730.
PMID: 31069604
Glucocorticoids (GC) are widely used in the treatment of SSc, although there is not much evidence to prove the benefits offered by these drugs in this disease. In this study,...
14.
Guimaraes Goncalves R, Dantas A, Pereira M, de Almeida A, Rego M, da Rocha Pitta I, et al.
Inflammation
. 2018 Oct;
42(2):412.
PMID: 30350227
One of the author's surname was incorrect. Anderson Ferreira de Almeida should be captured as Anderson Rodrigues de Almeida. The correct name is now presented above.
15.
Guimaraes Goncalves R, Dantas A, Pereira M, de Almeida A, Rego M, da Rocha Pitta I, et al.
Inflammation
. 2018 Oct;
42(2):407-411.
PMID: 30288636
Although statins have been successfully administered in the treatment of hypercholesterolemia and cardiovascular disease due to their lipid-lowering and anti-atherosclerotic action, they have shown immunomodulatory effects in several studies with...
16.
Dantas A, de Almeida A, Sampaio M, Cordeiro M, Oliveira P, de Ataide Mariz H, et al.
Immunol Lett
. 2018 Mar;
198:12-16.
PMID: 29601941
Immune dysregulation is a central process in the pathogenesis of systemic sclerosis (SSc). Cytokines produced by lymphocytes and monocytes are important mediators and induce tissue damage, recruit additional inflammatory cells,...
17.
Guimaraes Goncalves R, Pereira M, Dantas A, de Almeida A, Lopes Marques C, Rego M, et al.
Autoimmunity
. 2017 Dec;
51(1):1-9.
PMID: 29256263
Systemic sclerosis (SSc) is a multisystemic, complex, and rare disease of connective tissue, with high morbidity and mortality, and without specific treatment. The disease is characterized by three main principles:...
18.
Dantas A, de Almeida A, Sampaio M, Cordeiro M, da Rocha Jr L, Oliveira P, et al.
Steroids
. 2017 Sep;
127:24-30.
PMID: 28866045
In this study, we evaluated glucocorticoids (GC) effects on cytokine/chemokine levels in serum samples and peripheral blood mononuclear cell (PBMC) production from systemic sclerosis (SSc) patients. We evaluated cytokine and...
19.
Dantas A, Goncalves S, de Almeida A, Guimaraes Goncalves R, Sampaio M, de Melo Vilar K, et al.
Dis Markers
. 2016 Dec;
2016:6064830.
PMID: 27965520
. To determine active TGF-1 (aTGF-1) levels in serum, skin, and peripheral blood mononuclear cell (PBMC) culture supernatants and to understand their associations with clinical parameters in systemic sclerosis (SSc)...
20.
Dantas A, Goncalves S, Pereira M, de Almeida A, Lopes Marques C, Barreto de Melo Rego M, et al.
Autoimmunity
. 2015 Jun;
48(7):429-33.
PMID: 26057401
Background: Interferon (IFN)-λ1 is a newly described cytokine, member of type III interferons family, which is known for its antiviral, anti-proliferative and antitumor activity. Recent studies indicated that this cytokine...